Abstract

THE REVIEW OF REMDESIVIR

Vaibhav Shinde*, Dr. Pavan Avhad, Priti Somase, Pallavi Kadam, Yogini Chaudhari, Shubhangi Shinde

ABSTRACT

The corona virus (COVID-19) medicated infection a highly contagious respiratory illness that was intailly found in wuhan city of hubel province in china. The protein 7 BTE is an RNA-dependent RNA polymerse that a plays a crucial role in corona virus replication and transcription machinery and it appears to be the primary target of antiviral drug Remdesivir. The corona virus disease 2019 (COVID-19) pendamic has become a global health crisis. Considering the recend Food and Drug Administration (FDA) approval of Remdesivir as the first officially approved agent for COVID-19 treatment, we performed this systematic review and meta- analysis to evaluate the efficacy and safety of Remdesivir administration in COVID-19 patients. A systematic literature search was done through MEDLINE, goggle scholar, web of science, scopus, science direct, cochrane library, medRxiv and boiRxiv from their inception to December 22nd 2020. Five Randomized Controlled Trial (RCTs) and five Non Randomized Studies of Intervention (NRSI) were entered into the meta- analysis. The result showed that Remdesivir administration was associated a significant improvement in the 28 day recovery experiencing serious Adverse Drug Reactions (ADRs) was significantly lower (RR = 0.75, 95℅Cl, 0.63-0.90) in the Remdesivir group than the comparison / control group. The polled median difference of the time to clinical improvement was 2.99 (92% Cl = 2.71- 2.28) which did not remain significant during the sensitivity analysis. The clinical output comparison of the 5-day and 10-day Remdesivir courses revealed that the 5-day regimen might provide similar benefits while causing fewer serious ADRs than 10 day. Correct meta-analysis provided an updated evaluation scientific evidance on the use od Remdesivir in COVID-19 patients. Performing adequate well designed RCTs are needed to show more accurated result.

Keywords: Remdesivir; COVID-19; SARS-COV-2.